ISARIC4C and CO-CIN (Tier 0) feed data dynamically to Public Health Scotland, Public Health England, SPI-M, NERVTAG and SAGE. SPI-M have been highly productive and published several analysis that informed Policy.
ISARIC4C and CO-CIN data are used to inform the NHS England Independent Advisory Group concerning the use of neutralising monoclonal antibodies and anti-viral drugs in high-risk clinical subgroups.
Other key UK policy documents citing ISARIC4C / CO-CIN data
COVID-19: the green book, chapter 14a.
a. cites Docherty AB, et al. Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study https://doi.org/10.1136/bmj.m1985
b. Swann OV, et al. Clinical Characteristics of children and young people admitted to hospital with COVID-19 in United Kingdom: prospective multicentre observational cohort study https://doi.org/10.1136/bmj.m3249
Remdesivir – national prescribing guidance